Edward B. Skibo

Edward B. Skibo

Auto-generated profile, based on publicly available information

Edward B. Skibo

Department of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona 85287-1604, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ESEdward B. Skibo
Edward B. Skibo
CXChengguo Xing
Chengguo Xing
RDRobert T. Dorr
Robert T. Dorr

7 April 2009 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
OKOmar Khdour
Omar Khdour
ESEdward B. Skibo
Edward B. Skibo
In this article, we address the presence of the prekinamycin quinone methide using the techniques of spectral global fitting and the13C-labeling of the reactive centre. Two-electron reduction of a prekinamycin affords a long-lived quinone methide species that was characterised spectrally. A correlation was made between the calculated ΔE (kcal/mol) values for quinone methide tautomerisation and cytostatic activity to support the postulate that the quinone methide plays a role in prekinamycin biological activity. We also prepared a stable quinone methide of prekinamycin and studied its solution chemistry directly.

1 April 1996 in Synlett
Verified
Journal Article
Closed access
ESEdward B. Skibo
Edward B. Skibo
IIImadul Islam
Imadul Islam
WSWilliam G. Schulz
William G. Schulz
RZRu Zhou
Ru Zhou
LBLaura Bess
Laura Bess
RBRomesh Boruah
Romesh Boruah
Work in our laboratory has led to the development of the pyrrolo[1,2-a]benzimidazole-based antitumor agents. There are three structural classes of these agents: the 6-aziridinyl analogues (PBIs), the 6-acetamido analogues (APBIs), and the imino-6-acetamido analogues (imino-APBIs). These agents were prepared by multistep syntheses, all of which started with a pyrrolo[1,2-a]benzimidazole ring forming reaction utilizing the ”t-amino effect”. Enantiospecific synthesis were also carried out employing amino acids of known configuration and an ”internal” Phillips reaction. The chemistry of the rest of the steps leading to the PBIs, APBIs, and the imino-APBIs is presented. The aziridinyl ring of the PBIs is activated as an alkylating agent upon quinone reduction. In addition, the aziridinyl ring also traps a proton. This unprecedented reaction is very likely a [1,5]sigmatropic shift. Reductive alkylation of mononucleotides and DNA by PBIs result in alkylation of the phosphate oxygen anion. The reaction at this site is attributed to electronic factors as well as hydrogen bonding in the DNA major groove. The DNA alkylation reaction and resulting cleavage are likely responsible for the antitumor activity observed in the PBIs. The chemical events leading to APBI and imino-APBI antitumor activity are currently under study.


5 November 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ESEdward B. Skibo
Edward B. Skibo
XHXiaofen Huang
Xiaofen Huang
RMRogelio Martinez
Rogelio Martinez
RLRobert H. Lemus
Robert H. Lemus
WCWilliam A. Craigo
William A. Craigo
RDRobert T. Dorr
Robert T. Dorr

1 June 1998 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
ESEdward B Skibo
Edward B Skibo
This review presents a discussion of the design, chemistry, cytotoxicity and antitumour activity of agents based on the pyrrolobenzimidazole or azomitosene ring system. The focus is the 6-aziridinylquinone derivatives (PBIs) and 6-acetamidoquinone derivatives (APBIs) of this ring system (see Figure 1). Comparisons will be made with related benzimidazole and indole-based antitumour agent systems reported in the patent literature. The pyrrolobenzimidazoles will be shown to represent a new and useful class of antitumour agent with advantages over other such agents. The 6-aziridinyl derivatives (PBIs) alkylate and cleave DNA upon two-electron reduction as a result of phosphate alkylation by the protonated aziridine ring. In contrast, the 6-acetamido quinone derivatives (APBIs) do not require reductive activation to exert cytotoxicity. The 6-acetamido quinone derivatives act as DNA intercalating agents and inhibit the first step of topoisomerase II-mediated DNA relaxation. Some PBIs were found to exhibit high ...